Also, they reported that positive p16 status was associated with longer cancer-specific survival (HR: 0.36, 95% CI: 0.13–0.99), with the worst CSS was seen in patients with lymph node-positive disease, as well as double negative of p16 and p53 [74]. Here, TP53 is linked to cancer.